All Medical Marijuana Firms Are Not Created Equal

The health case for cannabis is gaining support from doctors as prominent as Sanjay Gupta, the Emmy-award winning neurosurgeon and chief medical correspondent for CNN. In 2013 and earlier this year, Gupta co-produced two documentaries on the medical benefits of marijuana titled Weed and Weed 2. Increasing awareness of the benefits could prompt more doctors to prescribe cannabis for their patients and could fuel consumer demand. The vitamin and nutraceutical supplement market in the United States is currently worth an estimated $20 billion.

Canada’s potentially huge medical marijuana market has been labeled “the Green Rush,” and Vancouver-based BC Chronic Inc. is pursuing a strategy that could leave even its largest competitors green with envy.

For context, the space has drawn serious investor attention as noted by impressive market activity. A few standout examples:

Affinor announced its plans to move into the space and has hit a recent 52-week high of $0.52 likely as a result that Vertical Design is taking a controlling (10%) stake in AFI.  Affinor has 58,188,898 shares outstanding with a market cap of $28,513,000 (May 20, 2014).

Tweed listed as the first Medical marijuana producer on the TSX.V, trading at $2.90. The Company just closed a $15 million bought deal financing. Tweed has 39,943,991 shares outstanding with a market cap of $115,840,000 (May 20, 2014).

To read more, visit http://markets.financialcontent.com/stocks/news/read/27267351/

Posted in: News

Comments are closed.